Ryazan State Medical University
Russia
Clinical Trials
20
Active:3
Completed:10
Trial Phases
2 Phases
Phase 4:1
Not Applicable:9
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Not Applicable
9 (90.0%)Phase 4
1 (10.0%)Myocardial Infarction in the Elderly
Recruiting
- Conditions
- Myocardial Infarction (MI)
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Ryazan State Medical University
- Target Recruit Count
- 1000
- Registration Number
- NCT06860646
- Locations
- 🇷🇺
State Budgetary Institution of the Ryazan Region "Regional Clinical Cardiology Dispensary", Ryazan, Russian Federation
PREDICTORS of CARDIOVASCULAR OUTCOMES in INDIVIDUALS with DIFFERENT OBESITY PHENOTYPES
Active, not recruiting
- Conditions
- Obesity and Obesity-related Medical Conditions
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Ryazan State Medical University
- Target Recruit Count
- 1600
- Registration Number
- NCT06806371
- Locations
- 🇷🇺
Ryazan State Medical University, Ryazan, Russian Federation
Effects of Bioflavanoids on Vascular Wall Remodeling in Patients With Varicose Veins
Not Applicable
Active, not recruiting
- Conditions
- Leg EdemaVascular DiseasesVaricose Veins of Lower LimbVarix
- Interventions
- Drug: "Venarus®" (diosmin and hesperidin)Other: Elastic compressionProcedure: Endovenous laser ablation (EVLA) with miniphlebectomyOther: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Ryazan State Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT06367166
- Locations
- 🇷🇺
RyazanSMU, Ryazan, Russian Federation
Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.
Not Applicable
Recruiting
- Conditions
- Peripheral Arterial Occlusive Disease
- Interventions
- Drug: PolypeptidesOther: Routine conservative treatmentDevice: Femoral-popliteal bypass grafting with a synthetic graft above the knee
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Ryazan State Medical University
- Target Recruit Count
- 120
- Registration Number
- NCT05933720
- Locations
- 🇷🇺
RyazanSMU, Ryazan, Russian Federation
Myocardial Fibrosis in Patients With Permanent Pacemakers
Active, not recruiting
- Conditions
- FibrosisAtrial FlutterAtrial Fibrillation
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Ryazan State Medical University
- Target Recruit Count
- 300
- Registration Number
- NCT05920226
- Locations
- 🇷🇺
Ryazan State Medical University, Ryazan, Russian Federation
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found